The effects of combination of gefitinib and cisplatin on tongue squamous cell carcinoma cell lines

J Cancer Res Ther. 2015 Jan-Mar;11(1):37-40. doi: 10.4103/0973-1482.147380.

Abstract

Objectives: To study the inhibitory effect of combining the gefitinib with cisplatin on tongue squamous cell carcinoma cells.

Materials and methods: Two cell lines were used, tca8113 which is a cisplatin-sensitive cell line, and tca8113/CDDP which is a cisplatin-resistant cell line established in Jiamusi University Laboratories. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was performed to calculate the IC 50 values of both drugs using both cell lines. Detection of Ras, Raf and ERK1/2 was done by using western blot technique after exposure to different concentrations of gefitinib and cisplatin.

Results: Tca8113/CDDP has shown more resistance to cisplatin than tca8113 and slightly more resistance to gefitinib than tca8113. Combination of the two drugs has shown to be more effective for both cell lines than when each alone even with lower concentrations.

Conclusions: Combination of gefitinib and cisplatin is a better choice than using each drug alone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Carcinoma, Squamous Cell / drug therapy
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cisplatin / pharmacology*
  • Dose-Response Relationship, Drug
  • Gefitinib
  • Humans
  • Quinazolines / pharmacology*
  • Tongue Neoplasms / drug therapy
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Cisplatin
  • Gefitinib